Search clinical trials for: sunitinib plus paclitaxel

Total 9097 results

Cogent Biosciences, Inc.

Recruiting

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Metastatic Cancer | Advanced Gastrointestinal Stromal Tumors

United States, Korea, Republic of, Spain, United Kingdom, Australia, France, Italy, Netherlands, Taiwan, Germany, Denmark, Hong Kong, Canada, Sweden, Norway, Mexico, Czechia, Argentina, Hungary, Brazil, Chile, Poland
Indiana University
Pfizer

Completed

Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer

Breast Cancer

United States
Pfizer

Withdrawn

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Carcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
Taipei Veterans General Hospital, Taiwan

Completed

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Taiwan
Shengjing Hospital

Recruiting

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Breast Cancer | Immunotherapy | Stereotactic Radiotherapy

China
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
Masonic Cancer Center, University of Minnesota

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Lung Cancer
University Health Network, Toronto
Pfizer

Completed

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma (SNIPP)

Pheochromocytoma | Paraganglioma

Canada, Netherlands
Sun Yat-sen University

Recruiting

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Breast Cancer

China
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma (NOTABLE-307)

Gastric or Esophagogastric Junction Adenocarcinoma
Genentech, Inc.

Terminated

A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Novartis Pharmaceuticals; Sai Life Sciences

Completed

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

Solid Tumors

United States
Hutchmed

Not yet recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Pfizer

Completed

Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors

Neoplasms

United States
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Tata Memorial Centre

Recruiting

Radiation Therapy in Unresectable Gall Bladder Cancer (RUGB)

Gall Bladder Cancer

India
Fudan University

Recruiting

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Breast Cancer

China
Genentech, Inc.

Terminated

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Non-Small Cell Lung Cancer
Pfizer

Completed

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, France, Canada
Eisai Limited

Completed

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Ovarian Cancer | Triple Negative Breast Cancer | Malignant Solid Tumour | Advanced Melanoma | B-cell Malignancy, Low-grade

United Kingdom
Mianyang Central Hospital

Unknown

Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus

Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University

Completed

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin for Stage Ⅱ-Ⅲ Esophageal Cancer Patients (nabPCESCC)

Esophageal Squamous Cell Carcinoma

China
Samsung Medical Center

Unknown

Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma (XP versus XT)

First Line Chemotherapy | Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel | Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Korea, Republic of
Qilu Hospital of Shandong University

Withdrawn

Neoadjuvant Immunotherapy to ESCC

Esophagus SCC

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer (CSAPPPCC)

Uterine Cervical Cancer

China
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
Hoosier Cancer Research Network
Pfizer

Completed

Sutent + Taxol for Advanced Esophageal Cancer

Esophageal Cancer

United States
AnewPharma

Unknown

Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer

Advanced Gastric Cancer

China
Jungsil Ro
Pfizer; HK inno.N Corporation

Completed

Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib (PGS)

Breast Cancer

Korea, Republic of
Loyola University
GlaxoSmithKline

Withdrawn

Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
Huazhong University of Science and Technology

Active, not recruiting

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Hallym University Medical Center

Recruiting

Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma

Gastric Cancer | Gastroesophageal-junction Cancer

Korea, Republic of
Pfizer

Completed

Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

Breast Neoplasms

United States
Chinese Society of Lung Cancer

Completed

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung (C-TONG1002)

Carcinoma, Non-Small-Cell Lung

China
Fudan University

Unknown

Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

Breast Cancer

China
AGO Study Group
Philipps University Marburg Medical Center; HSK Reasearch GmbH Wiesbaden

Completed

Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor

Platinum Refractory Epithelial Ovarian Cancer | Primary Cancer of the Peritoneum | Cancer of the Fallopian Tube

Germany
Fudan University
Fujian Cancer Hospital; Jiangsu Cancer Institute & Hospital; Ningbo No.2 Hospital and other collaborators

Recruiting

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Esophageal Squamous Cell Carcinoma | Survival | Chemoradiotherapy

China
Bayer

Terminated

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small Cell Lung

Belgium, Italy, Spain, Hong Kong, United States, Germany, United Kingdom, Chile, Taiwan, Australia, Canada, Argentina, Puerto Rico, France, Poland, Russian Federation, Sweden, Hungary, Netherlands, Brazil, Korea, Republic of
Shanghai Chest Hospital

Unknown

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Pulmonary Large Cell Neuroendocrine Carcinoma
Mothaffar Rimawi

Terminated

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer (CRIZENT)

Breast Cancer

United States
Jun Guo

Not yet recruiting

A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma

China
Fudan University

Completed

Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

Breast Cancer

China
Nanjing Luye Sike Pharmaceutical Co., Ltd.

Unknown

Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer

Breast Cancer

China
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery

Kidney Cancer

United States
Tianjin Medical University Cancer Institute and...
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Unknown

Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC

Esophageal Cancer Stage III | Esophageal Cancer Stage IIB

China
Shandong Cancer Hospital and Institute

Unknown

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Breast Cancer | HER2-positive Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Athenex, Inc.
PharmaEssentia; Zenith Technology Corporation Limited

Completed

A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel

Solid Tumor

New Zealand, Taiwan, Australia
WiSP Wissenschaftlicher Service Pharma GmbH
Bristol-Myers Squibb; Roche Pharma AG

Completed

Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer

Metastatic Breast Cancer

Germany
Pfizer

Completed

A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer

Breast Neoplasms

United States, Germany, Italy, Spain

3

Subscribe